CompletedNCT01072929
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolarity type I
Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 39 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 433
- Sponsor
- Cephalon
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01072929
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Get this study by email
Recruitment & locations
CompletedBirmingham · Beverly Hills · Garden Grove
36 more locations
- Imperial
- Irvine
- Oceanside
- San Diego
- Santa Ana
- Temecula
- Coral Springs
- Fort Myers
- Gainesville
- Jacksonville
- Lauderhill
- Orlando
- Tampa
- Atlanta
- Roswell
- Naperville
- Oak Brook
- Park Ridge
- Baltimore
- Fall River
- St Louis
- Mount Laurel
- Albuquerque
- Brooklyn
- New York
- Rochester
- Staten Island
- Raleigh
- Beachwood
- Dayton
- Salem
- Media
- Scranton
- Charleston
- Austin
- Bellevue
Questions about this study
Who is behind this study?
The study sponsor is Cephalon.
Did this study involve medication?
Yes. The study involved medication, including Armodafinil and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
